Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Next Previous
X
Search
Trial Profile

A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alisertib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Sep 2018 Primary endpoint (Six month progression free survival) has been met, as per the results published in the Clinical Cancer Research.
    • 19 Sep 2018 Primary endpoint (6 month radiographic progression free survival) has not been met, as per the results published in the Clinical Cancer Research
    • 19 Sep 2018 As per the results published in the Clinical Cancer Research, radiographic response rate was initially selected as the primary endpoint, the trial was amended after an interim analysis of the 1st 19 patients demonstrating limited responses but with clinical improvement and stable disease in patients with aggressive disease and limited treatment options. Based on recommendations of the steering committee, the primary endpoint was modified to 6 month radiographic progression free survival.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top